TapImmune is leading the charge in vaccine development specifically designed to target tumors and metastatic disease for ovarian and breast cancer. The company is using propriety nucleic acid-based immuno-therapeutics designed to comprehensively stimulate a patient’s killer T-cells and helper T-cells for best treatment outcomes.
TapImmune maintains high-value collaborations with the Mayo Clinic and other organizations including pharmaceutical giant AstraZeneca, Memorial Sloan Kettering, and the U.S. Department of Defense. These prestigious third party organizations represent further independent vetting of the company’s programs and technology.
TapImmune is in early Phase II trials with its landmark TPIV 200 vaccine that targets Folate receptor alpha for ovarian and breast cancer. There are nine sites enrolling triple negative breast cancer patients around the country and the company has received Fast Track approval designation and Orphan Drug status to expedite testing for ovarian cancer.
In The News
TapImmune is at the Forefront of Immuno-Oncology with T-Cell Therapeutics, and people are noticing.